Clinical Scorecard: Impact of Trismus on Quality of Life Related to Health in Head and Neck Cancer Survivors Up to a Decade After Completing Radiotherapy
At a Glance
Category
Detail
Condition
Trismus in Head and Neck Cancer Survivors
Key Mechanisms
Limited mouth opening due to tumor burden and radiotherapy-induced tissue damage.
Target Population
Head and neck cancer survivors treated with radiotherapy.
Care Setting
Oncologic treatment centers specializing in head and neck cancer.
Key Highlights
Trismus affects up to 33% of patients 3–10 years post-radiotherapy.
Health-related quality of life (HRQL) is significantly impacted by trismus.
Long-term HRQL trajectories show mixed outcomes after oncologic treatment.
Guideline-Based Recommendations
Diagnosis
Trismus defined as maximum interincisal opening (MIO) of ≤ 35 mm.
Management
Curative-intent radiotherapy combined with chemotherapy for advanced disease.
Monitoring & Follow-up
Assess MIO and HRQL at baseline, 12 months, 5 years, and 10 years post-treatment.
Risks
Increased pain, eating limitations, and diminished oral hygiene due to trismus.
Patient & Prescribing Data
Adults aged 18 and older with head and neck cancer.
Combination of radiotherapy and chemotherapy is standard for advanced cases.
Clinical Best Practices
Utilize validated questionnaires like EORTC QLQ-C30 and QLQ-HN35 for HRQL assessment.
Implement the Gothenburg Trismus Questionnaire for comprehensive trismus evaluation.
